The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells

AIDS

Volumn 23, Issue 15, 2009, Pages 2047-2050

  Shehu Xhilaga, Miranda ^a,b   Rhodes, David ^c   Wightman, Fiona ^a,b   Liu, Hong B ^d   Solomon, Ajantha ^a,b   Saleh, Suha ^a,b   Dear, Anthony E ^d   Cameron, Paul U ^a,b   Lewin, Sharon R ^a,b,e  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Avexa Ltd   (United States)

^d MONASH UNIVERSITY   (Australia)

^e BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; METACEPT 1; METACEPT 3; OXAMFLATIN; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL DEATH; CELL LINE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSCRIPTION INITIATION; VIRUS TRANSCRIPTION;

CELL DEATH; CELL LINE; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HIV-1; HUMANS; HYDROXAMIC ACIDS; SULFONAMIDES; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION; VIRUS LATENCY;

EID: 70349773324     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328330342c     Document Type: Article

References (29)

1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
2. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4R T cells. Nat Med 2003; 9:727-728.
3. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-ofconcept study. Lancet 2005; 366:549-555.
4. Steel A, Clark S, Teo I, Shaunak S, Nelson M, Gazzard B, et al. No change to HIV-1 latency with valproate therapy. AIDS 2006; 20:1681-1682.
5. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-836.
6. Khochbin S, Kao HY. Histone deacetylase complexes: functional entities or molecular reservoirs. FEBS Lett 2001; 494: 141-144.
7. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-1108.
8. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25:139-149.
9. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26:412-423.
10. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84-90.
11. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284:6782-6789.
12. Dear AE, Liu HB, Mayes PA, Perlmutter P. Conformational analogues of Oxamflatin as histone deacetylase inhibitors. Org Biomol Chem 2006; 4:3778-3784.
13. Sonoda H, Nishida K, Yoshioka T, Ohtani M, Sugita K. Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD. Oncogene 1996; 13:143-149.
14. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104:8071-8076.
15. Clouse KA, Robbins PB, Fernie B, Ostrove JM, Fauci AS. Viral antigen stimulation of the production of human monokines capable of regulating HIV1 expression. J Immunol 1989; 143: 470-475.
16. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4R T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007; 110:4161-4164.
17. Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, Corbeil J. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci USA 1997; 94:4653-4658.
18. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22:1868-1877.
19. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63:4460-4471.
20. Kwon SH, Ahn SH, Kim YK, Bae J-U, Yoon JW, Hong S, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002; 277:2073-2080.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
22. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
23. Valenzuela-Fernandez A, Alvarez S, Gordon-Alonso M, Barrero M, Ursa A, Cabrero JR, et al. Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol Biol Cell 2005; 16:5445-5454.
24. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61:8492-8497.
25. Sonnemann J, Gange J, Pilz S, Stötzer C, Ohlinger R, Belau A, et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 2006; 6:183.
26. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O. Determinants of HIV-1 latency establishment. J Virol 2009; 83:3078-3093.
27. Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000; 95:2378-2385.
28. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-20-deoxycytidine with valproic acid. Leuk Res 2005; 29:739-748.
29. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007; 97:177-182.